drugset / Trial / NCT07433517
VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors
Phase 0
Not yet recruiting
6 enrolled
Shanghai Jiao Tong University School of Medicine
Shanghai Vitalgen BioPharma Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
To evaluate the safety and tolerability of intracerebral injection of VGN-Ex05e in the nucleus accumbens of patients with autism spectrum disorder.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VGN-Ex05e | Unknown | 2e+06 cells | Other |
| Subject | VGN-Ex05e | Unknown | 6e+06 cells | Other |